This one is preventable — start here
HPV vaccination. Human papillomavirus causes almost all cervical cancer. The vaccine is routinely recommended at ages 11–12 (it can start at 9), with catch-up through age 26, and shared decision-making for some adults aged 27–45. It works best before any exposure, which is why it is given long before it could possibly be needed — that timing is the point, not an oversight. Boys and girls both: HPV also causes anal, penile and throat cancers.
Screening. Cervical screening finds changes before they become cancer. Typical U.S. recommendations: Pap test every 3 years from age 21; from 30 to 65, either HPV testing every 5 years, co-testing every 5 years, or a Pap every 3 years. Recommendations vary between organisations and are updated periodically, so confirm the current schedule with your clinician.
Vaccinated women still need screening. The vaccine covers most but not all high-risk HPV types. This is the most common and most consequential misunderstanding about cervical cancer prevention.
Countries with strong vaccination and screening programmes are on track to make cervical cancer rare. That is a genuinely achievable goal, and it depends on ordinary appointments.
Who is at risk
- Persistent infection with high-risk HPV — present in nearly all cases. HPV infection itself is extremely common and usually clears on its own; it is persistence that matters.
- Never screened or under-screened — the majority of cervical cancers occur in women who were not screened, or not followed up after an abnormal result.
- Smoking — roughly doubles risk in women with HPV.
- A weakened immune system — HIV, or immunosuppressive medication, which makes HPV far more likely to persist.
- Long-term oral contraceptive use (risk declines after stopping), and having several children.
- Early first sexual activity and multiple partners — because they raise the chance of HPV exposure, not for any other reason.
- DES exposure before birth — relevant to women whose mothers took diethylstilbestrol.
Finding it early
Screening is the whole story here, because early cervical cancer and precancer cause no symptoms at all. By the time symptoms appear, the disease is usually invasive.
Symptoms that need evaluation: bleeding after sex, bleeding between periods, bleeding after menopause, unusual or foul-smelling discharge, pelvic pain, or pain during sex. Later: leg swelling, back pain, or changes in urination or bowels.
An abnormal screening result is not cancer. Most abnormalities are HPV infection or low-grade changes that resolve on their own. What matters is completing the follow-up — colposcopy, repeat testing, or treatment of precancer — because abnormal results that are never followed up are one of the main routes to advanced cervical cancer. If you have had an abnormal result and lost track of the follow-up, ring the clinic.
Cervical cancer is most often diagnosed between 35 and 44 — a decade when many women are busiest and least likely to prioritise a screening appointment.
How it’s diagnosed
An abnormal screen leads to colposcopy — the cervix examined with a magnifying scope and a vinegar solution that highlights abnormal areas — with a biopsy of anything suspicious. It is uncomfortable rather than painful for most women.
Precancer (CIN 2/3) may be treated with LEEP (removing the abnormal area with a fine wire loop) or a cone biopsy. This is treatment of precancer — it prevents cancer rather than treating it.
If cancer is confirmed, staging involves examination, MRI of the pelvis to assess local extent, and PET/CT to check lymph nodes and distant spread. HIV testing is recommended, since immunosuppression changes management.
Staging explained simply
Cervical cancer uses the FIGO system, which now incorporates imaging and lymph node findings. Tumour size and node status drive the decision between surgery and chemoradiation more than the stage number alone.
| Stage | What it means in plain words |
|---|---|
| Stage I | Confined to the cervix. Very small tumours may be treated with surgery that preserves fertility. |
| Stage II | Beyond the cervix — upper vagina or tissue beside the uterus — but not to the pelvic wall. |
| Stage III | Reaches the pelvic wall or lower vagina, blocks a kidney tube, or involves pelvic or abdominal lymph nodes. |
| Stage IV | Invades bladder or rectum, or has spread to distant organs. |
Grading and biology
Precancer is graded separately from cancer, and the distinction is worth holding onto: CIN 1 usually resolves without treatment; CIN 2 and CIN 3 are treated to prevent progression. This is a genuine precancer stage — a window of years in which the disease can be stopped entirely.
Invasive cancer is graded 1–3 on how abnormal the cells appear. Type matters more: squamous cell carcinoma is the most common; adenocarcinoma arises higher in the canal, is harder for screening to catch, and is becoming proportionally more common; small cell neuroendocrine carcinoma is rare and aggressive.
Tumour size, depth of invasion, involvement of small blood or lymph vessels, and node status all shape the treatment plan.
How it’s treated
Very early disease can be treated with a cone biopsy or simple hysterectomy. Fertility-sparing surgery (trachelectomy — removing the cervix but keeping the uterus) is possible for selected small tumours in women who want children. Ask early, because it must be decided before other treatment starts.
Early-stage disease is treated with radical hysterectomy and lymph node assessment, or with radiation — both can be curative, and the choice depends on tumour size, your other health conditions and preference. For open radical hysterectomy specifically, trial evidence has favoured the open approach over minimally invasive surgery, which is worth discussing with your surgeon.
Locally advanced disease is treated with chemoradiation — and this is radiation-led curative treatment, not palliative. External pelvic radiation with weekly cisplatin, followed by brachytherapy, which places the radiation source directly at the cervix. Brachytherapy is not optional. Omitting it measurably worsens survival, and it is under-used in some settings. If you are being treated for locally advanced cervical cancer and brachytherapy has not been mentioned, ask about it explicitly.
Advanced and recurrent disease now involves immunotherapy alongside chemotherapy, which has improved survival.
Where CureRays fits: cervical cancer is one of the clearest examples of radiation as curative therapy. Brachytherapy technique — image guidance, applicator choice, dose to bladder and rectum — genuinely determines both cure and long-term function.
What the guidelines say
In broad strokes: prevent with HPV vaccination; screen on schedule and complete follow-up of abnormal results; treat precancer to prevent cancer; for early invasive disease offer surgery or radiation, with fertility-sparing surgery for selected small tumours; treat locally advanced disease with concurrent chemoradiation including brachytherapy; and add immunotherapy for advanced or recurrent disease.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Source: NCI SEER Cancer Stat Facts: Cervical Cancer, SEER 22 (excluding IL/MA), 2014–2020. Overall 5-year relative survival is 67.4%. In 2024 an estimated 13,820 women were diagnosed and about 4,360 died.
| When it is found | Share of cases | 5-year relative survival |
|---|---|---|
| Localized — confined to the cervix | 42% | 91.1% |
| Regional — spread to nearby lymph nodes | 36% | 60.8% |
| Distant — spread to other organs | 15% | 19.4% |
| Unstaged | 6% | 61.4% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
The number that should bother us is 42%. Only about four in ten cervical cancers are caught while still confined to the cervix, where survival is above 90%. For a cancer with a precancerous phase lasting years and a screening test that finds it, that figure represents missed appointments, missed follow-up after abnormal results, and unequal access — not a limitation of medicine.
The disparities are stark and worth naming. Incidence is highest among Hispanic (9.8 per 100,000), American Indian/Alaska Native (9.2) and Black (8.7) women, compared with 6.9 among non-Hispanic White women. Death rates are highest among Black (3.2) and American Indian/Alaska Native (3.0) women. These gaps largely track access to screening and follow-up rather than biology.
Side effects and how we watch for them
During chemoradiation: diarrhoea, urinary frequency and burning, fatigue, low blood counts, and skin irritation in the treated area. Most settles in the weeks after treatment.
Longer term: the pelvis is a crowded place, and honest counselling matters. Expect discussion of ovarian failure and early menopause (ovaries can sometimes be surgically moved out of the radiation field before treatment — ask about this before starting), vaginal narrowing and dryness, bowel and bladder changes, and lymphoedema. Fertility will be affected by pelvic radiation — raise preservation before treatment begins, because afterwards is too late.
Vaginal dilator use or continued sexual activity after treatment genuinely prevents narrowing, and makes future examinations possible. It is awkward to discuss and it matters.
How it is assessed: graded at each visit on a standard scale, with blood counts during chemoradiation. Report heavy bleeding, inability to pass urine, or fever promptly.
Follow-up, remission and survivorship
Remission means no detectable cancer. Most recurrences occur within two to three years, so follow-up is closest then — examination every 3–6 months, with imaging as indicated.
Survivorship after pelvic chemoradiation deserves active management rather than endurance: menopausal symptoms and bone density if the ovaries stopped working, vaginal health and sexual function, bowel and bladder symptoms, and lymphoedema. All of these have treatments, and all are commonly left unmentioned because they are embarrassing.
If you had a fertility-sparing procedure, pregnancies are managed as higher risk with a specialist obstetric team.
Questions people actually ask
I've had the HPV vaccine. Do I still need screening?
Yes. The vaccine prevents most but not all high-risk HPV types, and screening catches what remains. This is the single most important thing to get right about cervical cancer prevention.
My HPV test was positive. Do I have cancer?
No. HPV infection is extremely common and usually clears on its own. A positive test means you need appropriate follow-up, not that you have cancer or precancer.
Is it too late for me to get vaccinated?
Vaccination is routine at 11–12, with catch-up through 26, and shared decision-making for some adults 27–45. It works best before exposure, but it is a conversation worth having with your clinician rather than assuming you have missed the window.
What is brachytherapy and why does everyone insist on it?
It places the radiation source directly at the cervix, delivering a high dose exactly where it is needed while sparing surrounding organs. For locally advanced cervical cancer, omitting it measurably lowers cure rates. It is a necessary part of curative treatment, not an optional extra.
Can I still have children?
For very early cancers, fertility-sparing surgery may be possible — but it must be decided before other treatment starts. Pelvic radiation causes infertility, so raise fertility preservation at the first appointment rather than later.
I missed my screening for years. Is there any point now?
Yes, absolutely. Go now. Most cervical cancers occur in women who were not screened or not followed up, and screening still finds precancer and early cancer regardless of how long the gap has been. Nobody will lecture you.
Informational only, not medical advice — confirm with your care team.
Go deeper on cervical cancer
Read the full plain-language guide, or ask our radiation team about chemoradiation and brachytherapy.